Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions

Terada, Yukiko; Kamoi, Koju; Ohno‐Matsui, Kyoko; Yamano, Chinami; Coler‐Reilly, Ariella; Yamano, Yoshihisa

doi:10.1097/md.0000000000006021

Cited by 20 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another report by Terada et al showed recurrence of human T-cell leukaemia-lymphoma virus 1 (HTLV-1) uveitis and HTLV-1-associated myelopathy/tropical spastic paraparesis with tocilizumab administration. HTLV-1 symptoms improved with steroid-based therapy but worsened again with abatacept substitution 88. The authors called for caution with the use of biologics in HTLV-1-infected individuals.…”

Section: Resultsmentioning

confidence: 99%

Ocular side effects of antirheumatic medications: a qualitative review

et al. 2020

View full text Add to dashboard Cite

TopicThis paper reviews the ocular side effects of medications used in the treatment of rheumatological conditions.Clinical relevanceRheumatic diseases are inflammatory conditions that may affect the skin, blood vessels, joints, muscles and internal organs. Immunosuppressive agents are often used as treatment and while powerful, they carry side effects and toxicities that need careful monitoring. Ophthalmic complications have been reported with the use of antirheumatic medications; however, there is a lack of literature synthesising these reports. This paper addresses this gap and hopes to inform both rheumatologists and ophthalmologists as they work together on the management of patients with rheumatological conditions.MethodsPubMed literature search was conducted from November to September 2019 searching for ocular side effects with the use of 25 rheumatological drugs.ResultsA total of 111 papers were included in this review. Adverse side effects were divided into non-infectious and infectious causes. Traditional disease-modifying antirheumatic drugs (DMARDs) were associated with pruritus, irritation and dryness of the conjunctiva while biologic DMARDS showed reports of new-onset/recurrent uveitis and demyelinating conditions. Infectious side effects included episodes of cytomegalovirus retinitis, toxoplasmic chorioretinitis and endophthalmitis. Other serious side effects were encountered and included in this review.ConclusionThe goal of this paper is to inform healthcare providers about potential ocular side effects from rheumatological medications. Healthcare providers are encouraged to learn more about these ophthalmic complications and find relevance within their clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Ocular side effects of antirheumatic medications: a qualitative review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The peak age at uveitis onset was in the 50s followed by the 60s for women, and in the 60s followed by the 70s for men, according to one recent survey (Terada et al, 2017b), which showed that age at onset had increased compared with previous research. Women greatly outnumbered men among HU patients (Takahashi et al, 2000;Terada et al, 2017a).…”

Section: Htlv-1 Uveitismentioning

confidence: 85%

“…Tumor necrosis factor (TNF)-blocking biologics were first introduced for inflammatory diseases, with other biologics such as IL-6-blocking agents introduced subsequently. Recently, we experienced a case in which a patient with RA and HTLV-1 infection received an IL-6-blocking agent, which reactivated HTLV-1 and induced HU in the eye (Terada et al, 2017b). We have since been cautious of the risk of newly developed molecularly targeted drugs reactivating HTLV-1 and inducing ocular inflammation.…”

Section: Current Concernsmentioning

confidence: 99%

HTLV-1 in Ophthalmology

Kamoi

2020

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

Human T-cell leukemia virus type 1 (HTLV-1) was the first retrovirus described as a causative agent for human disease. In the field of ophthalmology, a close relationship between HTLV-1 infection and uveitis was identified through a series of clinical and laboratory studies in the late 1980s-1990s. Since then, HTLV-1-related ocular manifestations such as keratoconjunctivitis sicca, interstitial keratitis, optic neuritis and adult T-cell leukemia/lymphoma (ATL)-related ocular manifestations have continuously been reported. During the three decades since the association between HTLV-1 and ocular pathologies was discovered, ophthalmic practice and research have advanced with the incorporation of new technologies into the field of ophthalmology. Accordingly, new findings from recent research have provided many insights into HTLV-1-associated ocular diseases. Advanced molecular technologies such as multiplex polymerase chain reaction (PCR)/broad-range PCR using ocular samples have enabled rapid and accurate diagnosis. Advanced ophthalmic technologies such as widefield fundus camera and optical coherence tomography (OCT) have clarified various features of HTLV-1-associated ocular manifestations, and identified characteristics such as the "knob-like ATL cell multiple ocular infiltration" (KAMOI) sign. Advanced drug delivery methods such as intravitreal injection and sub-Tenon injection have led to progress in preventing disease progression. This article describes global topics and the latest research findings for HTLV-1-associated ocular diseases, with reference to a largescale nationwide survey of ophthalmologists. Current approaches and unmet needs for HTLV-1 infection in ophthalmology are also discussed.

show abstract

“…We must also consider the effect of the DMARDs that patients with RA are receiving. Indeed, worsening symptoms of both HAM/TSP and HTLV-1-associated uveitis were reported in an HTLV-1-positive patient with RA who received treatment with a soluble IL-6 receptor inhibitor (Terada et al, 2017). More recently, a high incidence of HAM/TSP in renal transplantation recipients from HTLV-1positive donors was reported (Yamauchi et al, 2019).…”

Section: Development Of Atl and Ham/tsp In Htlv-1-positive Patients Wmentioning

confidence: 99%

HTLV-1 Infection and Rheumatic Diseases

Umekita

Okayama

2020

Front. Microbiol.

View full text Add to dashboard Cite

Some major research and clinical questions about human T-cell leukemia virus type 1 (HTLV-1) infection and rheumatic diseases remain: (1) Does HTLV-1 infection cause rheumatic diseases? (2) Do patients with rheumatic diseases display different responses to treatment with anti-rheumatic agents when they are HTLV-1 carriers? (3) Is adult T-cell leukemia/lymphoma (ATL) or HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) more prevalent in HTLV-1 carriers with rheumatic diseases who are treated with anti-rheumatic agents? These questions are important because increasing numbers of patients with rheumatic diseases are currently receiving treatment with aggressive medicines such as immunosuppressants and biologics. Studies on HTLV-1 gene-transgenic mice have shown manifestations resembling rheumatic diseases. Epidemiological studies have shown a high incidence of HTLV-1 infection in patients with rheumatic diseases including rheumatoid arthritis (RA), Sjogren's syndrome, and polymyositis. HTLV-1-positive and HTLV-1-negative patients with RA have displayed similar immunological features including the seroprevalence of anticitrullinated peptide antibodies. Conversely, attenuated effectiveness of tumor necrosis factor inhibitors for HTLV-1-positive patients with RA in Japan has been reported. Therefore, although no direct evidence has shown that HTLV-1 infection alone causes rheumatic diseases, HTLV-1 may affect the inflammation of RA. Although the incidence of ATL or HAM/TSP among patients with rheumatic diseases has not been investigated in large-scale studies, ATL or HAM/TSP has developed among HTLV-1-positive patients with rheumatic diseases. HTLV-1 infection may affect the clinical course of patients with rheumatic diseases, particularly after receiving anti-rheumatic agents. Because studies on these issues are limited, further investigation with large sample sizes is necessary.

show abstract

Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions

Cited by 20 publications

References 30 publications

Ocular side effects of antirheumatic medications: a qualitative review

Ocular side effects of antirheumatic medications: a qualitative review

HTLV-1 in Ophthalmology

HTLV-1 Infection and Rheumatic Diseases

Contact Info

Product

Resources

About